Welcome to our dedicated page for Vera Therapeutics news (Ticker: VERA), a resource for investors and traders seeking the latest updates and insights on Vera Therapeutics stock.
Vera Therapeutics, Inc. (Nasdaq: VERA) is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases, with a particular emphasis on autoimmune kidney disorders such as immunoglobulin A nephropathy (IgAN). The VERA news page on Stock Titan aggregates company press releases and third-party coverage so readers can follow key clinical, regulatory, and corporate developments affecting the stock.
News about Vera Therapeutics frequently centers on its lead product candidate, atacicept, an investigational fusion protein targeting BAFF and APRIL. Recent announcements include submission and U.S. FDA Priority Review of a Biologics License Application for atacicept in adults with IgAN, supported by data from the ORIGIN Phase 2b and ORIGIN 3 Phase 3 trials. The company has highlighted statistically significant and clinically meaningful reductions in proteinuria and a safety profile described as comparable to placebo, as well as presentations at major scientific meetings and publication of trial results in The New England Journal of Medicine.
Investors and followers of VERA stock can also expect news on pipeline expansion and broader immunology programs. Vera Therapeutics reports ongoing evaluation of atacicept in expanded IgAN populations and other autoimmune kidney diseases, along with development of VT-109, a next-generation BAFF/APRIL-targeting fusion protein licensed from Stanford University, and MAU868, a monoclonal antibody designed to neutralize BK virus infection in kidney transplant recipients.
In addition, the news flow includes capital markets and corporate updates, such as underwritten public offerings of Class A common stock, at-the-market sales agreements, inducement equity grants under the company’s 2024 Inducement Plan, and changes in board composition or executive roles disclosed via Form 8-K. Vera Therapeutics also announces participation in healthcare and investor conferences, where its management team presents clinical data and corporate strategy.
By reviewing the VERA news page regularly, readers can track how clinical milestones, regulatory decisions, financing activities, and governance changes may relate to Vera Therapeutics’ development programs and its position as a late clinical-stage biotech issuer.
Vera Therapeutics, a clinical-stage biotechnology company, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, from 3:45-4:25 PM ET. CEO Marshall Fordyce will lead the presentation and engage in one-on-one investor meetings during the event, taking place virtually from January 10-13, 2022. A live audio webcast of the presentation will be available online, with a replay accessible for 30 days. The company focuses on innovative treatments for serious immunological diseases, including its lead product candidate, atacicept, targeting autoimmune disorders.
Vera Therapeutics has announced the acquisition of MAU868, a first-in-class monoclonal antibody targeting BK Virus (BKV) infections, which is a significant cause of kidney transplant failure. The transaction involves an upfront payment of $5 million and potential milestone payments totaling $7 million. Vera has also secured a $50 million credit facility with Oxford Finance to support further development. MAU868 is currently in a Phase 2 clinical trial, with results expected in mid-2022. This acquisition aligns with Vera’s strategy to enhance its pipeline for immunological diseases.
Vera Therapeutics announces the appointment of Kimball Hall to its board of directors. Hall, with over 30 years of experience in the pharmaceutical industry, is recognized for her leadership roles at Genentech and Amgen, and her current position as president of Abzena, a contract development and manufacturing organization. Her expertise in drug manufacturing and strategic development is expected to enhance Vera's objectives, particularly in advancing its lead clinical candidate, atacicept, aimed at treating serious immunological diseases.
Vera Therapeutics (Nasdaq: VERA), a biotechnology company focused on immunological diseases, announced that its CEO, Marshall Fordyce, will present at several investor conferences in November 2021. These include the Jefferies London Healthcare Conference (November 16-18) and the Evercore ISI HealthCONx (November 30 - December 2). Fordyce's presentations will discuss Vera’s lead product candidate, atacicept, aimed at treating autoimmune diseases. Replay links for all presentations will be available for 30 days on the company’s website.
Vera Therapeutics reported ongoing progress in its Phase 2a JANUS clinical trial for atacicept, showing substantial and durable reductions in serum Gd-IgA1 levels in patients with IgA nephropathy. Key highlights include a 60% reduction in Gd-IgA1 for the 75mg dose, indicating potential for renal survival benefits. Financially, Vera posted a net loss of $7.6 million for Q3 2021, with $86.2 million in cash as of September 30, 2021. The company is advancing the Phase 2b ORIGIN study and awaits FDA feedback on its lupus nephritis development strategy.
The Phase 2a JANUS clinical trial for atacicept, conducted by Vera Therapeutics, demonstrated a significant and durable reduction in serum galactose-deficient IgA1 (Gd-IgA1) over 72 weeks in patients with IgA nephropathy (IgAN). The trial revealed that atacicept 75mg lowered serum Gd-IgA1 levels to the lowest risk quartiles, highlighting its potential to improve renal survival. These findings were presented at the American Society of Nephrology Kidney Week 2021. The company anticipates further results from the ongoing Phase 2b ORIGIN trial to clarify the implications of these reductions on renal function.
Vera Therapeutics announces the upcoming presentation of clinical data for its lead product candidate, atacicept, from the Phase 2a JANUS clinical trial in patients with IgA nephropathy (IgAN). The data will be shared during an ePoster session at the American Society of Nephrology Kidney Week 2021, held virtually from November 4-7, 2021. The presentation, titled 'Atacicept Reduces Serum Gd-IgA1 by Quartiles in IgAN Patients', will feature critical findings aimed at advancing treatments for this immunological disease.
Vera Therapeutics, Inc. (Nasdaq: VERA) will host a KOL webinar on IgA Nephropathy on September 20, 2021. The event will include presentations by experts Richard Lafayette, M.D., and Jonathan Barratt, Ph.D., focusing on the efficacy of atacicept in treating IgAN. Atacicept targets B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), with promising clinical trial data supporting its potential as a best-in-class therapy. The webinar will allow attendees to ask questions after the presentations.
Vera Therapeutics, Inc. (Nasdaq: VERA) reported its Q2 2021 financial results, highlighting significant clinical and financial advancements. They initiated the Phase 2b clinical trial named 'ORIGIN' for atacicept in IgA nephropathy patients, aiming to establish it as the first disease-modifying therapy for this condition. The company reported a net loss of $3.4 million, with cash and equivalents totaling $91.6 million as of June 30, 2021, bolstered by IPO proceeds. The management team expanded with the appointment of Sean Grant as Chief Financial Officer.
Vera Therapeutics announced the appointment of Sean Grant as Chief Financial Officer, effective immediately. With nearly 15 years in financial services, he brings expertise from CareDx and Citigroup, focusing on strategic investments and capital markets. CEO Marshall Fordyce emphasized Grant's significant experience will enhance the company's financial strategies as it develops its lead candidate atacicept, aimed at treating immunological diseases. Atacicept is expected to help patients with conditions like IgA nephropathy, addressing a market with no existing disease-modifying treatments.